C5AR1 and glomerulosclerosis: Further, using a highly specific C5aR1 antagonist, PMX53, our group has shown that the inhibition of C5aR1 attenuated albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis, as well as restoration of the loss of anti-inflammatory Tregs in C57BL/6J mice after 20 weeks of streptozotocin-induced diabetes (140).